Mirum Pharmaceuticals, Inc. - common stock (MIRM)

Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage powerhouse in the rare liver disease sector. As of early 2026, the company stands as a beacon of growth in the biotechnology landscape, recently surpassing annual revenue targets and achieving [...]

Don't wait too long to make a decision on these three stocks.

Focused on rare liver disease therapies, this biopharma company reported a significant insider sale amid strong one-year stock gains.

Not all of these predictions may come true. But at least a few of them will likely do so.

These predictions were easy.

Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface.

Mirum Pharmaceuticals is a mid-cap biotech stock to keep your eyes on.

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.

Discover MIRM stock: A high-growth biotech with accelerating earnings, strong revenue, and a bullish technical setup poised for a potential breakout.

Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.

One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds.

This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline.

Mirum Pharmaceuticals (MIRM) shows strong revenue growth and a positive technical setup, presenting a compelling case for momentum investors seeking breakout opportunities.

Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout.

Mirum Pharmaceuticals (MIRM) shows strong growth momentum with 62% revenue growth and a bullish technical breakout pattern, making it a top biotech stock to watch.

MIRUM Pharmaceuticals (MIRM) is a high-growth stock exhibiting a strong technical uptrend and robust revenue growth, making it a standout candidate for momentum investors.

Mirum Pharmaceuticals beats Q2 2025 estimates with $127.8M revenue, narrows losses, and raises full-year guidance. Stock surges 8.6% post-earnings.